Innovative Pharmaceutical Patents: To be patentable, an invention must be new and inventive.

Q: Requirements for Patentability

To qualify for patent protection, an invention must be: New: The requirement of novelty is absolute and worldwide. An invention that has already been disclosed anywhere in the world cannot be patented in South Africa. Inventive: The invention must not be obvious to a person skilled in the relevant technical field. It must demonstrate a real inventive step beyond existing knowledge.

Patents play a vital role in encouraging innovation across all industries, but nowhere is their impact felt more strongly than in the pharmaceutical field. Medicines and treatments that improve – and often save – lives are the result of years of costly research and development. Patents give inventors the opportunity to protect their investment, while also ensuring that knowledge is eventually shared with the public.

Patents Encouraging Innovation in the Pharmaceutical field

What is a Patent?

In South Africa, the Patents Act defines a patent as a certificate serving as proof that an invention has been granted patent protection within the Republic. Put simply, a patent is an exclusive right granted to an applicant or patent holder for a limited period – generally up to 20 years. This right allows the holder to exclude others from manufacturing, using, or exploiting the invention during that time.

In exchange for this protection, the patent holder must disclose information about the invention, enabling the public to freely use it once the patent has expired. Importantly, there is no such thing as a “worldwide patent.” Applicants must apply separately in each country where protection is sought.

Requirements for Patentability

To qualify for patent protection, an invention must be:

Pharmaceutical Patents and Special Considerations

Pharmaceutical inventions are subject to the same requirements of novelty and inventiveness as any other patent. However, the Patents Act includes certain nuances specific to the life sciences.

For example, Section 25(11) excludes methods of medical treatment or diagnosis from being patentable in South Africa. This means that while medicines and medical devices can be patented, the way a doctor or paramedic uses them to treat patients cannot. The rationale is to prevent restrictions on patient care and ensure that healthcare professionals can carry out life-saving procedures without the risk of infringing a patent.

Case Studies: Prozac and Viagra

The global pharmaceutical industry has seen many high-profile patent battles. Two well-known examples illustrate the complexity of patent law in this field:

Prozac (Fluoxetine): Developed by Eli Lilly, Prozac was initially protected by two patents. The last was due to expire in 2003, but a U.S. court invalidated it earlier after finding it lacked inventiveness compared to the first. The result was that generic versions entered the market sooner, significantly reducing Prozac’s market share.
Viagra (Sildenafil): Originally patented by Pfizer to treat cardiovascular conditions, Viagra’s unexpected effect on erectile dysfunction emerged during trials. Pfizer attempted to patent this second medical use, but because the information had already been publicly disclosed, it was no longer considered novel. This case highlights how novelty and inventiveness apply even when a medicine is repurposed for new conditions.

Access to Medicines: A Balancing Act

Pharmaceutical patents highlight the tension between innovation and accessibility. On one hand, patents reward innovation by allowing companies to recoup research costs and continue developing new medicines. On the other, there is a strong moral and social argument for making life-saving treatments widely accessible, especially in developing countries.

In South Africa, the Treatment Action Campaign (TAC) brought this issue into sharp focus, advocating for affordable access to HIV treatment. The debate remains highly relevant today, particularly in the context of global health challenges such as pandemics and vaccine distribution.

Conclusion

Pharmaceutical patents are essential in driving innovation, but they also raise difficult questions about affordability and access to healthcare. By carefully balancing these competing interests, patent law aims to protect both the rights of inventors and the broader public interest.

Case Studies: Prozac and Viagra

The global pharmaceutical industry has seen many high-profile patent battles. Two well-known examples illustrate the complexity of patent law in this field:

Prozac (Fluoxetine): Developed by Eli Lilly, Prozac was initially protected by two patents. The last was due to expire in 2003, but a U.S. court invalidated it earlier after finding it lacked inventiveness compared to the first. The result was that generic versions entered the market sooner, significantly reducing Prozac’s market share.
Viagra (Sildenafil): Originally patented by Pfizer to treat cardiovascular conditions, Viagra’s unexpected effect on erectile dysfunction emerged during trials. Pfizer attempted to patent this second medical use, but because the information had already been publicly disclosed, it was no longer considered novel. This case highlights how novelty and inventiveness apply even when a medicine is repurposed for new conditions.